Every S-3 that Karyopharm Therapeutics Inc (KPTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow KPTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPTI filings page.
Karyopharm Therapeutics Inc. filed a registration statement to register the resale of up to 8,843,036 shares of its common stock. The shares consist of 1,030,354 outstanding shares, 3,391,164 shares issuable upon exercise of pre-funded warrants and 4,421,518 shares issuable upon exercise of warrants. The company will receive no proceeds from resale; it agreed to pay registration expenses pursuant to a registration rights agreement related to a March 2026 private placement that generated approximately $30 million in gross proceeds. The prospectus discloses a 9.99% beneficial ownership limitation on warrant exercises and describes distribution methods including ordinary brokerage transactions, block trades and privately negotiated sales.
Karyopharm Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $400,000,000 of securities, including debt, common stock, preferred stock, units and warrants. The filing includes an at-the-market sales agreement with Jefferies to sell up to $100,000,000 of common stock from time to time. The prospectus describes general terms and states proceeds will be used for general corporate purposes. The document incorporates prior SEC reports by reference and discloses an Ernst & Young LLP audit opinion noting an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Karyopharm Therapeutics Inc. filed a resale registration covering up to 2,805,688 shares of common stock to be offered from time to time by selling stockholders. The registered amount consists of 1,487,917 outstanding shares and 1,317,771 shares issuable upon exercise of outstanding warrants.
The company is not selling any securities in this offering and will not receive proceeds from sales by the selling stockholders. Karyopharm would receive cash only if holders exercise warrants for shares at the stated exercise price. The shares may be sold through various customary methods and at market or negotiated prices.
As context, 17,050,876 shares were outstanding as of October 30, 2025
Karyopharm Therapeutics (KPTI) filed an S-3 prospectus for a resale of up to 9,569,707 shares of common stock by selling stockholders. The registration covers 949,908 shares already issued in recent financing transactions, 956,885 shares issuable upon exercise of outstanding pre-funded warrants, 4,950,947 shares issuable upon exercise of outstanding warrants with a $6.64 exercise price, and 2,711,967 shares issuable upon conversion of 9.00% Senior Convertible Notes due 2028, subject to customary limits.
The company stated it will not receive proceeds from sales by selling stockholders. It would receive cash only upon any cash exercises of warrants. The shares may be sold from time to time using methods described under “Plan of Distribution.”
As context, shares outstanding were 17,050,876 as of October 30, 2025. Examples of registered resale allocations include Braidwell Partners Master Fund LP 2,134,699 and Entities affiliated with Highbridge Capital Management, LLC 2,843,292.